Imatinib: the first 3 yearsCAPDEVILLE, Renaud; SILBERMAN, Sandra; DIMITRIJEVIC, Sasa et al.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 5, pp S77-S82, issn 1359-6349Conference Paper

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjectsDUTREIX, Catherine; BIN PENG; MEHRING, Guenther et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 4, pp 290-294, issn 0344-5704, 5 p.Article

Imatinib: A targeted clinical drug developmentCAPDEVILLE, Renaud; SILBERMAN, Sandra.Seminars in hematology. 2003, Vol 40, Num 2, pp 15-20, issn 0037-1963, 6 p., SUP2Conference Paper

Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinibMCLEAN, Lee Anne; GATHMANN, Insa; CAPDEVILLE, Renaud et al.Clinical cancer research. 2004, Vol 10, Num 1, pp 155-165, issn 1078-0432, 11 p., 1Article

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaDRUKER, Brian J; TALPAZ, Moshe; SAWYERS, Charles L et al.The New England journal of medicine. 2001, Vol 344, Num 14, pp 1031-1037, issn 0028-4793Article

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjectsBOLTON, Ann E; BIN PENG; HUBERT, Martine et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 2, pp 102-106, issn 0344-5704, 5 p.Article

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignanciesSIU, Lillian L; ROWINSKY, Eric K; SKLENAR, Ivo T et al.Clinical cancer research. 2002, Vol 8, Num 7, pp 2157-2166, issn 1078-0432Article

Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocationO'BRIEN, Stephen G; VIEIRA, Sara A. D; CONNORS, Samantha et al.Blood. 2002, Vol 99, Num 9, pp 3465-3467, issn 0006-4971Article

Bioequivalence, safety, and tolerability of imatinib tablets compared with capsulesNIKOLOVA, Zariana; PENG, Bin; HUBERT, Martine et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 5, pp 433-438, issn 0344-5704, 6 p.Article

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: Follow-up resultsKANTARJIAN, Hagop M; TALPAZ, Moshe; KORNBLAU, Steven M et al.Clinical cancer research. 2002, Vol 8, Num 7, pp 2177-2187, issn 1078-0432Article

Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)DRESSMAN, Marlene A; MALINOWSKI, Rachel; MCLEAN, Lee Anne et al.Clinical cancer research. 2004, Vol 10, Num 7, pp 2265-2271, issn 1078-0432, 7 p.Article

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsDEMETRI, George D; VON MEHREN, Margaret; FLETCHER, Jonathan A et al.The New England journal of medicine. 2002, Vol 347, Num 7, pp 472-480, issn 0028-4793Article

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyTALPAZ, Moshe; SILVER, Richard T; HOCHHAUS, Andreas et al.Blood. 2002, Vol 99, Num 6, pp 1928-1937, issn 0006-4971Article

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studySAWYERS, Charles L; HOCHHAUS, Andreas; FISCHER, Thomas et al.Blood. 2002, Vol 99, Num 10, pp 3530-3539, issn 0006-4971Article

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patientsBIN PENG; HAYES, Michael; CAPDEVILLE, Renaud et al.Journal of clinical oncology. 2004, Vol 22, Num 5, pp 935-942, issn 0732-183X, 8 p.Article

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 studyCHAMPAGNE, Martin A; CAPDEVILLE, Renaud; KRAILO, Mark et al.Blood. 2004, Vol 104, Num 9, pp 2655-2660, issn 0006-4971, 6 p.Article

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'BRIEN, Stephen G; GUILHOT, Francois; LECHNER, Klaus et al.The New England journal of medicine. 2003, Vol 348, Num 11, pp 994-1004, issn 0028-4793, 11 p.Article

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with Imatinib mesylateKANTARJIAN, Hagop M; O'BRIEN, Susan; GARCIA-MANERO, Guillermo et al.Clinical cancer research. 2002, Vol 8, Num 7, pp 2167-2176, issn 1078-0432Article

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosomeDRUKER, Brian J; SAWYERS, Charles L; KANTARJIAN, Hagop et al.The New England journal of medicine. 2001, Vol 344, Num 14, pp 1038-1042, issn 0028-4793Article

Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European ConsortiumGEOERGER, Birgit; MORLAND, Bruce; HAIN, Sharon et al.European journal of cancer (1990). 2009, Vol 45, Num 13, pp 2342-2351, issn 0959-8049, 10 p.Article

Phase I/II study of imatinib mesylate for recurrent malignant gliomas : North american braintumor consortium study 99-08WEN, Patrick Y; YUNG, W. K. Alfred; GILBERT, Mark et al.Clinical cancer research. 2006, Vol 12, Num 16, pp 4899-4907, issn 1078-0432, 9 p.Article

Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: Results from a Phase II multicenter studyPLESS, Miklos; BELHADJ, Karim; MÜLLER, Christian et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1299-1305, issn 1078-0432, 7 p.Article

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaKANTARJIAN, Hagop; SAWYERS, Charles; TALPAZ, Moshe et al.The New England journal of medicine. 2002, Vol 346, Num 9, pp 645-652, issn 0028-4793Article

A phase 2 study of imatinib in patients with relapsed or refractory philadelphia chromosome-positive acute lymphoid leukemiasOTTMANN, Oliver G; DRUKER, Brian J; BACCARANI, Michele et al.Blood. 2002, Vol 100, Num 6, pp 1965-1971, issn 0006-4971, 7 p.Article

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CMLO'DWYER, Michael E; MAURO, Michael J; KURILIK, Gwen et al.Blood. 2002, Vol 100, Num 5, pp 1628-1633, issn 0006-4971, 6 p.Article